{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=9&sponsor=Incyte+Corporation", "query": { "sponsor": "Incyte Corporation", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 408, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=10&sponsor=Incyte+Corporation&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=8&sponsor=Incyte+Corporation&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T10:05:24.541Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04577014", "title": "Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Soft Tissue Sarcoma", "Sarcoma,Soft Tissue", "Sarcoma", "Soft Tissue Sarcoma Adult" ], "interventions": [ { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2020-09-29", "completion_date": "2027-09-29", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-17T10:05:24.541Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04577014" }, { "nct_id": "NCT03978637", "title": "Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bronchiolitis Obliterans Syndrome" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2020-02-04", "completion_date": "2023-10-13", "has_results": true, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-10-17T10:05:24.541Z", "location_count": 7, "location_summary": "Los Angeles, California • Boston, Massachusetts • Durham, North Carolina + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03978637" }, { "nct_id": "NCT04582539", "title": "To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Multiple Myeloma", "Anemia" ], "interventions": [ { "name": "INCB000928", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2021-08-19", "completion_date": "2024-08-15", "has_results": true, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-17T10:05:24.541Z", "location_count": 8, "location_summary": "Palo Alto, California • Miami, Florida • Sarasota, Florida + 5 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04582539" }, { "nct_id": "NCT02265510", "title": "An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "INCB052793", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" }, { "name": "pomalidomide", "type": "DRUG" }, { "name": "INCB050465", "type": "DRUG" }, { "name": "INCB039110", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2014-09-10", "completion_date": "2019-02-27", "has_results": true, "last_update_posted_date": "2020-04-17", "last_synced_at": "2026-10-17T10:05:24.541Z", "location_count": 14, "location_summary": "Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02265510" }, { "nct_id": "NCT05127421", "title": "Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Ruxolitinib cream", "type": "DRUG" }, { "name": "Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 77, "start_date": "2021-11-10", "completion_date": "2023-09-29", "has_results": true, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-10-17T10:05:24.541Z", "location_count": 1, "location_summary": "Culver City, California", "locations": [ { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05127421" }, { "nct_id": "NCT03954236", "title": "Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-sclerotic Cutaneous Chronic Graft-versus-host Disease" ], "interventions": [ { "name": "topical ruxolitinib 1.5% cream", "type": "DRUG" }, { "name": "Topical vehicle/moisturizer cream", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 24, "start_date": "2019-05-14", "completion_date": "2027-02-06", "has_results": true, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-17T10:05:24.541Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03954236" }, { "nct_id": "NCT05755438", "title": "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prurigo" ], "interventions": [ { "name": "Ruxolitinib Cream", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 204, "start_date": "2023-03-10", "completion_date": "2025-08-13", "has_results": true, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-17T10:05:24.541Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Clarkston", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05755438" }, { "nct_id": "NCT00778700", "title": "A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Placebo Cream", "type": "OTHER" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 199, "start_date": "2008-10-28", "completion_date": "2009-06-26", "has_results": true, "last_update_posted_date": "2022-02-09", "last_synced_at": "2026-10-17T10:05:24.541Z", "location_count": 28, "location_summary": "Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 25 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Vallejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00778700" }, { "nct_id": "NCT02614612", "title": "Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graft-versus-host Disease (GVHD)" ], "interventions": [ { "name": "Itacitinib (200 mg)", "type": "DRUG" }, { "name": "Itacitinib (300 mg)", "type": "DRUG" }, { "name": "prednisone or methylprednisolone (corticosteroids)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2015-12", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2019-03-08", "last_synced_at": "2026-10-17T10:05:24.541Z", "location_count": 23, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 20 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02614612" }, { "nct_id": "NCT05359692", "title": "INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Head and Neck Squamous Cell Carcinoma", "Advanced Malignancies", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "INCAGN01876", "type": "BIOLOGICAL" }, { "name": "retifanlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2023-03-01", "completion_date": "2025-01-11", "has_results": false, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-10-17T10:05:24.541Z", "location_count": 17, "location_summary": "Birmingham, Alabama • La Jolla, California • Palo Alto, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05359692" } ] }